CCL2 and cancer: Anti-IL-6 antibody (Siltuximab) is proven to have an anti-cancer effect and decreases not only CCL-2, but also VEGF and CXCL-12 expression (Sawa-Wejksza and Kandefer-Szerszen 2018) (see Fig. 1).